Fresenius SE & Co KGaA
XMUN:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
|
BW Offshore Ltd
F:XY81
|
BM |
|
Industria de Diseno Textil SA
MAD:ITX
|
ES |
|
W
|
Whitehaven Coal Ltd
F:WC2
|
AU |
|
Aramark
NYSE:ARMK
|
US |
|
T
|
Terumo Corp
F:TUO
|
JP |
|
C
|
Cerro De Pasco Resources Inc
CNSX:CDPR
|
CA |
|
S
|
Singapore Telecommunications Ltd
F:SIT4
|
SG |
|
S
|
Skyworks Solutions Inc
XBER:AWM
|
US |
|
Warner Bros Discovery Inc
F:J5A
|
US |
|
Jtc PLC
LSE:JTC
|
JE |
|
S
|
SPAR Group Ltd
XBER:S8A
|
ZA |
|
A
|
Altria Group Inc
DUS:PHM7
|
US |
Fresenius SE & Co KGaA
Fresenius SE & Co KGaA is a healthcare company that makes medical products and runs hospitals. Its product side, Fresenius Kabi, sells things like IV fluids, injectable medicines, clinical nutrition products, infusion pumps, and other supplies used in hospitals and clinics. Its hospital side treats patients through large hospital networks in Germany and Spain, where it provides inpatient care, surgeries, and related medical services. The company makes money in two main ways. First, it sells healthcare products to hospitals, pharmacies, and other medical providers. Second, its hospital businesses are paid by insurers, public health systems, and patients for treatment and procedures. That mix gives Fresenius a role on both sides of the healthcare system: it supplies the tools doctors need and also delivers the care itself. What makes Fresenius different is that it sits close to the core of everyday healthcare rather than selling optional consumer products. Demand for its services and supplies is tied to surgery, chronic illness treatment, and routine hospital care, which makes the business easy to understand: when hospitals need dependable medical consumables and when patients need care, Fresenius is often part of the chain.
Fresenius SE & Co KGaA is a healthcare company that makes medical products and runs hospitals. Its product side, Fresenius Kabi, sells things like IV fluids, injectable medicines, clinical nutrition products, infusion pumps, and other supplies used in hospitals and clinics. Its hospital side treats patients through large hospital networks in Germany and Spain, where it provides inpatient care, surgeries, and related medical services.
The company makes money in two main ways. First, it sells healthcare products to hospitals, pharmacies, and other medical providers. Second, its hospital businesses are paid by insurers, public health systems, and patients for treatment and procedures. That mix gives Fresenius a role on both sides of the healthcare system: it supplies the tools doctors need and also delivers the care itself.
What makes Fresenius different is that it sits close to the core of everyday healthcare rather than selling optional consumer products. Demand for its services and supplies is tied to surgery, chronic illness treatment, and routine hospital care, which makes the business easy to understand: when hospitals need dependable medical consumables and when patients need care, Fresenius is often part of the chain.
Guidance raised: Fresenius lifted full-year core EPS growth guidance to 10% to 15% at constant currency, up from 5% to 10%, after a strong first half and broad-based performance across the group.
Strong quarter: Q2 organic revenue rose 6%, EBIT increased 10% at constant currency, and core EPS grew 14% at constant currency, with margin expansion across both Kabi and Helios.
Kabi strength: Fresenius Kabi posted 7% organic revenue growth and a 17% EBIT margin, helped by fast-growing biopharma, strong MedTech execution, and solid nutrition performance.
Helios resilient: Helios delivered 5% organic revenue growth and a 10.6% EBIT margin, and management said its 2027 outlook for EBIT growth remains unchanged despite the new German reimbursement law.
Cash and balance sheet: Operating cash flow and free cash flow were strong, leverage stayed at 2.6x net debt-to-EBITDA, and management said the balance sheet gives the company more flexibility to invest in growth.
Pipeline build-out: The company highlighted progress in biosimilars, including regulatory acceptance for vedolizumab, FDA approval for Rituximab biosimilars, and continued launch momentum for Tyenne, Denosumab, Idacio, and Bomyntra.
